1
Cary L Queen, Man Sung Co, William P Schneider, Nicholas F Landolfi, Kathleen L Coelingh, Harold E Selick: Humanized immunoglobulins. Protein Design Labs, Townsend & Townsend & Crew, December 2, 1997: US05693762 (1197 worldwide citation)

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immuno ...


2
Nicholas F Landolfi: Chimeric ligand/immunoglobulin molecules and their uses. Protein Design Labs, Townsend and Townsend Khourie and Crew, September 20, 1994: US05349053 (184 worldwide citation)

Chimeric molecules having a ligand component linked to an immunoglobulin constant region component are provided for various diagnostic, therapeutic and other uses. These immunoligands can exhibit the high degree of specificity associated with the ligand, yet retain various effector functions charact ...


3
Maximiliano Vasquez, Nicholas F Landolfi, Naoya Tsurushita, Cary L Queen: Humanized antibodies to &ggr;-interferon. Protein Design Labs, Townsend and Townsend and Crew, December 11, 2001: US06329511 (63 worldwide citation)

The invention provides humanized immunoglobulins that bind to and neutralize &ggr;-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.


4
Chung Nan Chang, Nicholas F Landolfi, Ulrich Martin: Monoclonal antibodies specific for the platelet derived growth factor .beta. receptor and methods of use thereof. Protein Design Labs, Boehringer Mannheim, Morrison & Foerster, March 16, 1999: US05882644 (35 worldwide citation)

The invention relates to monoclonal antibodies, humanized monoclonal antibodies and functional derivatives thereof specific for the platelet-derived growth factor receptor .beta.. Methods of use of the antibody, particularly in ameliorating restenosis, are also provided.


5
Marna Williams, J Yun Tso, Nicholas F Landolfi, Gao Liu: Therapeutic use of anti-CS1 antibodies. Abbott Biotherapeutics, Dechert, August 30, 2011: US08008450 (7 worldwide citation)

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of p ...


6
Balaji Balasa, Naoya Tsurushita, Nicholas F Landolfi: Treatment of inflammatory bowel diseases with anti-IP-10 antibodies. Abbott Biotherapeutics, May 3, 2011: US07935793 (6 worldwide citation)

The present invention is directed to high affinity anti-human IP-10 antibodies or antigen-binding fragments of these antibodies, including chimeric, humanized or fully human antibodies. The present invention is also directed to a method of reducing the severity of at least one symptom of an inflamma ...


7
Marna Williams, J Yun Tso, Nicholas F Landolfi, David B Powers, Gao Liu: Therapeutic use of anti-CS1 antibodies. Facet Biotech Corporation, Dechert, May 4, 2010: US07709610 (4 worldwide citation)

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of p ...


8
Maximiliano Vasquez, Nicholas F Landolfi, Naoya Tsurushita, Cary L Queen: Humanized antibodies to gamma-interferon. PDL BioPharma, Townsend and Townsend and Crew, February 27, 2007: US07183390 (3 worldwide citation)

The invention provides humanized immunoglobulins that bind to and neutralize γ-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.


9
Marna Williams, J Yun Tso, Nicholas F Landolfi, Gao Liu: Therapeutic use of anti-CS1 antibodies. AbbVie Biotherapeutics, Dechert, May 21, 2013: US08445646 (2 worldwide citation)

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of p ...


10
Nicholas F Landolfi, Naoya Tsurushita, Paul R Hinton, Shankar Kumar: Amphiregulin antibodies and their use to treat cancer and psoriasis. PDL Biopharma, Michael Biro, Susan Harlocker, May 29, 2007: US07223393 (2 worldwide citation)

The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer c ...